Investment Rating - The report assigns a "Buy" rating for the company, indicating a positive outlook for future performance [6][7]. Core Insights - The company is positioned as an innovative leader in the CDMO (Contract Development and Manufacturing Organization) sector, focusing on providing customized R&D and manufacturing services for pharmaceutical and biotech companies globally. The company's revenue has shown a compound annual growth rate (CAGR) of 20.67% from 2019 to 2024, with a projected revenue of 51.61 billion yuan in 2024 [1][3]. - The company's contract manufacturing revenue has significantly increased, accounting for 75% of total revenue in 2024, with international revenue making up 79.12% of total sales [2][3]. - The global CDMO market is experiencing robust growth, with an expected market size of $168.4 billion by 2028 and $338.5 billion by 2030, which the company is well-positioned to benefit from [3][4]. Summary by Sections Financial Performance - The company's revenue increased from 20.17 billion yuan in 2019 to 51.61 billion yuan in 2024, with a net profit growth from 2.38 billion yuan in 2019 to 10.33 billion yuan in 2023. However, net profit in 2024 was impacted by non-recurring losses, dropping to 6.06 billion yuan, a decrease of 41.34% year-on-year. In Q1-Q3 2025, net profit rebounded to 7.48 billion yuan, up 18.51% year-on-year [1][7]. Business Strategy - The company has a clear strategic focus on innovative drug CDMO services, with a growing pipeline of projects in peptide and conjugated nucleic acid technologies. The company is expanding its production capacity for peptides to 800 kg/year and is establishing commercialization capabilities for small nucleic acids [4][7]. Market Outlook - The report highlights the high market demand for innovative drugs, which is driving the growth of the CDMO sector. The company is expected to benefit from this trend, with projected revenues of 56.70 billion yuan, 62.78 billion yuan, and 69.57 billion yuan for 2025, 2026, and 2027, respectively [7][9].

Group 1: Automotive Industry - Changan Automobile plans to invest 225 million yuan to enter the robotics sector, establishing Changan Tian Shu Intelligent Robot Technology Co., Ltd. with a total registered capital of 450 million yuan [2][3] - The new company aims to leverage humanoid robot technology to drive Changan's strategic transformation from a traditional automaker to an "intelligent technology ecosystem platform" [3] - The humanoid robotics sector is seen as a significant growth opportunity, with Changan's strong position in data accumulation, supply chain integration, and financial strength potentially leading to enhanced valuation and business synergies in the long term [3][4] Group 2: Vaccine Industry - The vaccine industry continues to see breakthroughs in internationalization and research, with companies like Kangtai Biotech and Zhifei Biological making significant progress in vaccine development [6][9] - The demand for flu vaccines is expected to rise, especially among high-risk groups, as the seasonal flu activity increases [8][9] - The vaccine sector is experiencing structural differentiation, with a focus on innovation and international expansion as key strategies for long-term growth [14][15] Group 3: Medical Services - The medical services sector has shown resilience, with a recent increase in demand driven by seasonal illnesses, despite ongoing cost control pressures from insurance policies [21] - The State Council's initiative to promote provincial-level medical insurance coordination is expected to enhance the efficiency of healthcare resources and provide structural opportunities for the medical industry [19][20] - Investment recommendations focus on high-growth companies in the pharmaceutical outsourcing and consumer healthcare sectors, indicating a positive outlook for the medical services industry [21]

Investment Rating - The industry rating is "Overweight" (first coverage) [4][55] Core Views - The sector has consistently underperformed the market, but is expected to benefit from a market style switch [3][54] - The current valuation is at historical lows, indicating potential for upward movement [7][54] - The report suggests focusing on three key areas within the home appliance industry for investment opportunities [8][55] Summary by Sections Industry Performance - Year-to-date, the home appliance sector has increased by only +7.82%, ranking 21st among 31 Shenwan first-level industries, underperforming the CSI 300 index which rose by +15.04% [6][54] - The main contributors to the sector's performance have been the home appliance components sub-industry, while air conditioning and washing machines have shown stagnation [6][54] Valuation Analysis - The current price-to-earnings (PE) ratio for the home appliance industry is 14.85 times, ranking 27th among 31 Shenwan industries [7][54] - The PE ratio's percentile rank over the past 10 years is only 25.2%, indicating a low valuation compared to the CSI 300 index's 78.2% [7][54] Investment Recommendations - Focus on leading companies in the air conditioning and washing machine sectors, which have stable market shares and strong cash flows, with dividend yields between 4-7% and PE ratios of 7-14 times [8][55] - Consider leading companies in the kitchen and small home appliance segments, as there are opportunities for earnings expectations to improve due to resilient domestic demand and potential increases in overseas demand [8][55] - In the context of style switching and valuation increases, many small and mid-cap companies with low valuations may exhibit significant market capitalization elasticity [8][55]

Macro Strategy - In October, industrial enterprise profits showed a significant decline, with a year-on-year drop from 21.60% in September to -5.5% in October, leading to a cumulative year-on-year growth rate decrease from 3.20% to 1.90% [2] - The A-share market experienced a rebound from November 24 to November 28, with major indices such as the Shanghai Composite Index rising by 1.40% and the ChiNext Index increasing by 4.54% [3][4] - The rebound in A-shares was attributed to a reversal in the market's previous downward momentum, driven by a shift in expectations regarding the Federal Reserve's interest rate decisions and a recovery in the technology sector [3][4] Industry and Company Analysis Traditional Chinese Medicine Industry - The Traditional Chinese Medicine (TCM) sector saw a slight increase of 1.29% last week, the smallest among secondary sub-sectors in the pharmaceutical industry [9] - The price index for TCM materials showed a slight increase of 0.4%, indicating a recovery in market conditions and improved investor sentiment [12] - Multiple regions have initiated price governance for traditional Chinese medicine, aiming to create a unified and competitive market structure [13] Investment Recommendations - The report maintains an "overweight" rating for the TCM industry, suggesting three main investment themes: 1. Price governance, focusing on companies with strong R&D capabilities and unique products that can benefit from price reductions [15] 2. Consumption recovery, driven by macroeconomic improvement and increased health awareness among the aging population, favoring leading TCM brands [16] 3. State-owned enterprise reform, which is expected to enhance performance and create investment opportunities [16] - Recommended stocks include Zhaoli Pharmaceutical and Yiling Pharmaceutical, with a focus on companies with strong R&D capabilities and unique products [16]

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [6][54]. Core Viewpoints - The IVD market is expected to benefit from a recent policy initiative aimed at enhancing the adaptability of supply and demand for consumer goods, with a focus on high-end medical devices and efficient IVD equipment [5][53]. - The domestic biochemical diagnostics sector has largely overcome reliance on foreign technologies, indicating a completed process of localization [6][54]. - The report emphasizes the shift towards home health management, moving from a treatment-centered to a prevention-centered approach, which is expected to create a trillion-yuan integrated market [5][53]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 2.67%, with the IVD sector increasing by 2.63% during the week [2][12]. - The IVD sector's current PE ratio is 39.84X, with a PB ratio of 1.85X, reflecting a slight increase from the previous week [4][33]. Company Performance - Notable performers in the medical services sector include Haobio (+14.3%), Shuoshi Biological (+13.6%), and Innotech (+13.3%) [3][29]. - Underperformers include *ST Dongyang (-7.2%) and New Industry (-5.7%) [3][29]. Investment Recommendations - The report suggests focusing on companies in the IVD sector that cater to home consumption scenarios, such as Shengxiang Biological and Sannuo Biological [5][54]. - It highlights the importance of monitoring the growth potential in immunodiagnostics, particularly in chemiluminescence and molecular diagnostics like PCR [6][54].

证券研究报告 2025 年 11 月 30 日 湘财证券研究所 核心要点： 行业研究 证券行业周报 两融余额维持高位，日均交易量小幅回落 相关研究： 1.《行业周报：成交额小幅回落， 融资余额持续增长》 2025.10.19 行业评级：增持（维持） 近十二个月行业表现 % 1 个月 3 个月 12 个月 相对收益 -3 -12 -18 绝对收益 -7 -11 -2 -20% -10% 0% 10% 20% 30% 2024/11/28 2025/1/28 2025/3/28 2025/5/28 2025/7/28 2025/9/28 2025/11/28 沪深300 证券Ⅱ(申万) 注：相对收益与沪深 300 相比 分析师：张智珑 证书编号：S0500521120002 Tel：(8621) 50295363 Email：zzl6599@xcsc.com 地址：上海市浦东新区银城路88号 中国人寿金融中心10楼 ❑ 市场回顾：板块 PB 估值回落至 33%分位数 根据 Wind 数据，上周（11.24-11.28）上证指数上涨 1.4%，沪深 300 指数 上涨 1.6%，创业板指上涨 4.5%。申万非银金融 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [1] Core Views - Vaccine companies are achieving breakthroughs in internationalization and research and development, while the pressure for winter epidemic prevention continues to highlight the need for effective measures [4][9] - The vaccine industry is transitioning from scale expansion to innovation-driven growth, with supply-demand imbalances and homogenized competition causing short-term challenges, but the long-term outlook remains positive due to supportive policies, increasing demand, and technological advancements [9][28] Summary by Sections Recent Developments - Zhifei Biological's subsidiary obtained a U.S. patent for an RSV vaccine, marking a significant step in its international market strategy [3] - Watson Bio's subsidiary received a marketing license for a 13-valent pneumonia vaccine in Egypt, enhancing its international presence [3] - Wuhan Institute of Biological Products achieved important progress in children's vaccine development, with two vaccines approved for clinical use [3] Market Performance - The vaccine sector saw a 1.33% increase last week, underperforming compared to other pharmaceutical sectors [5][6] - Year-to-date, the vaccine sector has experienced a cumulative decline of 5.12% [6] Valuation Metrics - The vaccine sector's PE (ttm) is 95.41X, with a PB (lf) of 1.87X, indicating a slight increase in valuation metrics compared to previous periods [7] Investment Recommendations - The vaccine industry is under pressure, with a focus on innovation and international expansion as key strategies for recovery [8] - Companies with high technical barriers and differentiated pipelines are recommended for investment, particularly those with strong research and development capabilities [9][28]

Investment Rating - The industry rating is maintained at "Overweight" [8] Core Views - The market performance of the traditional Chinese medicine (TCM) sector showed a slight increase of 1.29%, which is the smallest among secondary sub-sectors [1] - The price governance of Chinese patent medicines is being actively implemented across multiple regions, aiming to create a unified and competitive drug market [4][5] - The valuation metrics for the TCM sector indicate a PE (ttm) of 27.72X and a PB (lf) of 2.33X, with both metrics showing slight increases compared to the previous week [2] Market Performance - The TCM sector reported a market index of 6501.99 points, reflecting a 1.29% increase over the last week [1] - The overall pharmaceutical and biological sector index rose to 8430.03 points, with a 2.67% increase [1] Valuation Metrics - The TCM sector's PE (ttm) is at 27.72X, up by 0.36X week-on-week, with a one-year maximum of 30.26X and a minimum of 24.72X [2] - The PB (lf) stands at 2.33X, increasing by 0.02X from the previous week, with a one-year maximum of 2.54X and a minimum of 2.17X [2] Supply Chain Insights - The market for TCM raw materials has shown signs of recovery, with a price index of 225.55 points, reflecting a 0.4% increase from the previous week [3] - The market sentiment for TCM raw materials is improving, with increased foot traffic and positive investment sentiment [3] Policy and Regulatory Environment - Multiple regions have initiated price governance for Chinese patent medicines, focusing on high-priced products with significant price discrepancies [4][5] - The ongoing supply-side reforms are expected to reshape competitive factors within the industry, with a shift from channel-driven to value and cost-driven competition [5] Investment Recommendations - The report suggests focusing on three main investment themes: price governance, consumption recovery, and state-owned enterprise reform [11] - Specific recommendations include companies with strong R&D capabilities, unique products, and those less affected by centralized procurement [12]

Investment Rating - The industry investment rating is maintained at "Overweight" [3][41] Core Insights - The rare earth magnetic materials industry has rebounded by 2.6% this week, outperforming the benchmark (CSI 300) by 0.96 percentage points. The industry valuation (TTM P/E) has increased by 1.85 times to 71.79, currently at 85.5% of its historical percentile [5][12] - The supply side of the rare earth segment is generally tight, with some separation enterprises experiencing reduced operating rates due to maintenance or raw material issues, leading to a tight supply of oxides. The demand side shows stable domestic orders and a gradual recovery in overseas market demand, indicating a steady increase in downstream demand [40][41] - The report suggests that the price and prosperity of the industry are expected to continue to rise, supported by tightening supply expectations and improving export demand following the easing of export controls [10][41] Summary by Sections Industry Performance - Over the past 12 months, the industry has shown a relative return of -8% over one month, -18% over three months, and a positive 50% over twelve months. Absolute returns are -11%, -17%, and 67% respectively [4] - The rare earth concentrate prices have generally rebounded, with domestic mixed rare earth carbonate prices rising by 2.78% to 37,000 CNY/ton, and imported monazite prices increasing by 4.95% to 53,000 CNY/ton [9][14] Price Trends - The price of praseodymium and neodymium has continued to rise, with praseodymium oxide averaging 567,000 CNY/ton (up 3.28%) and neodymium metal averaging 688,000 CNY/ton (up 2.69%) [16][17] - Dysprosium prices have continued to decline, with dysprosium oxide averaging 1,475 CNY/kg (down 0.67%) and dysprosium metal averaging 1,430 CNY/kg (down 1.72%) [20] - The price of neodymium-iron-boron blanks has stabilized before rising, with N35 averaging 142.5 CNY/kg (up 3.64%) and H35 averaging 212.5 CNY/kg (up 2.41%) [36] Investment Recommendations - The report maintains an "Overweight" rating for the industry, emphasizing the potential benefits for upstream rare earth resource companies due to tightening supply expectations and strategic value positioning. It also highlights the recovery of profitability and valuation premiums for downstream magnetic material companies, particularly those with strong customer structures and growth potential, such as Jinli Permanent Magnet [10][42]

Group 1 - The median return of active quantitative funds for the week of November 24-28, 2025, was 3.02%, outperforming the CSI 300 index at 1.64% and the Wind All A index at 2.90% [3][8] - For the year, the median return of active quantitative funds was 24.89%, compared to 15.04% for the CSI 300 index and 23.57% for the Wind All A index [3][8] - The top-performing active quantitative funds this week had returns between 6% and 8%, with a focus on the computer and electronics sectors [3][8] Group 2 - The "Super Expected Stock Selection Strategy" constructs a stock pool based on net profit exceeding expectations and analyst expectations, using the Wind All A index as the base stock pool [5][14] - For the week of November 24-28, 2025, the selected strategy yielded a return of 3.00%, exceeding the benchmark index by 0.09% [5][16] - For the year, the selected strategy achieved a return of 43.91%, significantly outperforming the benchmark index by 20.34% [5][19] Group 3 - The top 30 selected stocks for November 2025 were concentrated in the machinery sector, with the highest return from Joyoung Co., Ltd. (002242.SZ) at 8.63% [6][20] - The highest-performing active quantitative funds for the year had returns ranging from 58% to 119%, primarily focused on the electronics and machinery sectors [11][12] - The lowest-performing active quantitative funds for the year had returns between -11% and 0%, with a concentration in the food and beverage sector [11][13]